BSX NYSE
Boston Scientific Corporation
1W: +1.2%
1M: +3.8%
3M: -1.0%
YTD: -51.9%
1Y: -55.5%
3Y: -9.8%
5Y: +6.5%
$45.08
-0.51 (-1.11%)
After Hours: $45.15 (+0.07, +0.17%)
Weekly Expected Move ±3.5%
$42
$44
$46
$47
$49
Credit Risk of going bust: lower than 62% of companies Debt: 16.0% of company value Bonds: $51.9M held by 128 funds, 63 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.79 (down 98%), Boston Scientific Corporation would be worth roughly what it owes.
Total debt $12.62B against a stock market value of $66.06B.
Distance to default 6.42 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.10B (short-term plus half of long-term), stock volatility 39.6%; Altman Z 3.05. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.79 (down 98%), Boston Scientific Corporation would be worth roughly what it owes.
Total debt $12.62B against a stock market value of $66.06B.
Distance to default 6.42 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $7.10B (short-term plus half of long-term), stock volatility 39.6%; Altman Z 3.05. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships6
As Filer
counterparties named
3
As Counterparty
mentioned by others
2
Rel. Types
2024-01-08
Earliest Filing
2026-02-26
Latest Filing
target: 4
partner: 2
Counterparties (Filed by BSX)
6 relationshipsCompanies named in BSX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Penumbra, Inc. | PEN | target | Target company in the acquisition referenced as the closing condition for the 364-Day Revolving Credit Agreement. | 2026-02-26 | View |
| Penumbra, Inc. | PEN | target | Target company in a merger agreement with Boston Scientific Corporation. | 2026-01-15 | View |
| American Medical Systems Europe B.V. | AIG | partner | Issuer of the senior notes and wholly owned finance subsidiary of Boston Scientific Corporation. | 2024-02-27 | View |
| Axonics, Inc. | — | target | Target company to be acquired by Boston Scientific Corporation in the Axonics Acquisition. | 2024-02-27 | View |
| U.S. Bank Trust Company, National Association | — | partner | Trustee under the Indenture governing the senior notes. | 2024-02-27 | View |
| Axonics, Inc. | — | target | Target company in a merger agreement with Boston Scientific Corporation. | 2024-01-08 | View |
Mentioned As Counterparty
3 mentionsOther companies that named BSX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| PEN Penumbra Inc | target | Acquiring Penumbra, Inc. in a merger transaction | 2026-01-15 | View |
| ELUT ELUTIA INC. | target | Buyer of CIED Business assets | 2025-10-07 | View |
| ELUT ELUTIA INC. | target | Acquired the Cardiac Implantable Electronic Device Business from Elutia Inc. | 2025-09-09 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-07 | Officer/Director Change; Other Events; Exhibits | View | |
| 2026-09-23 | Officer/Director Change | View | |
| 2026-09-08 | Other Events | View | |
| 2026-08-26 | Other Events | View | |
| 2026-07-29 | Earnings Release; Exhibits | View | |
| 2026-07-27 | Exit/Disposal Costs | View | |
| 2026-05-18 | Other Events; Exhibits | View | |
| 2026-05-18 | Other Events; Exhibits | View | |
| 2026-05-05 | Bylaws Amendment; Shareholder Vote; Exhibits | View | |
| 2026-04-22 | Earnings Release; Exhibits | View | |
| 2026-03-30 | Other Events; Exhibits | View | |
| 2026-02-26 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Creation of | Agreement | View |
| 2026-02-23 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Other Events; Fi | View | |
| 2026-02-05 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-02-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-15 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-15 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-11-19 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-10-23 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-22 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR